Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression ...
Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood ...
Adia Med, the medical division of Adia Nutrition Inc. (OTC Pink: ADIA), proudly announces its ongoing registration with the ...
Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy ...
Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...
Med is proud to announce a strategic partnership with an FDA-approved laboratory in the field of regenerative medicine. This ...
The mucopolysaccharidosis market is witnessing a surge in innovation, driven by cutting-edge gene therapies, enzyme replacement treatments, and novel drug developments. The market is poised for ...
Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier ...
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Adia Med, the medical division of Adia Nutrition Inc. (OTC Pink: ADIA), proudly announces its ongoing registration with the State of Florida's ...
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...
Nonselective β-blockers may delay haematopoietic cell engraftment after transplantation, especially when combined with ...